VXRT News and Press, Vaxart Inc. From 11/08/19

Noteworthy events during the week of November 10 - 16 for healthcare investors. More news on: Ocular Therapeutix, Inc., Y-mAbs Therapeutics, Inc., Amarin Corporation plc, Healthcare stocks news, , Read more ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it will host a key opinion leader (KOL) meet...

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that four new members have been appointed to the ...

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced it will be presenting data from the recently comp...

Thinly traded nano cap Vaxart ( VXRT -9.4% ) is down on a 16x surge in volume in response to its $8M capital raise . Specifically, it is offering ~26.7M common shares, each with an accompanying five-year warrant to purchase one share at $0.30, at at combined price of $0.30. It is also off...

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten publ...

Vaxart (NASDAQ: VXRT ) is up  2%  premarket following positive topline results from Phase 1b safety , immunogenicity and interference study with its oral tableted bivalent norovirus vaccine in healthy adults. More news on: Vaxart, Inc., Healthcare stocks news, Read more ... ...

Both norovirus vaccines induced substantial immune responses with no indication of immunological interference when administered concurrently Phase 2-ready oral norovirus vaccine targets potential $3B+ market opportunity SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 (GLOBE NEWSWIRE)...

The following slide deck was published by Vaxart, Inc. in conjunction with this Read more ...

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company update and overview at the H.C....